NASDAQ:EPZMEpizyme Stock Price, Forecast & News

$18.58

+0.11 (+0.60 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$18.30

Now: $18.58▼

$18.81

50-Day Range

$13.68

MA: $17.06▼

$18.75

52-Week Range

$9.73

Now: $18.58▼

$27.82

Volume604,372 shs

Average Volume699,001 shs

Market Capitalization$1.88 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.06

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Epizyme has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.71, Epizyme has a potential upside of 65.3% from its current price of $18.58.
Amount of Analyst Coverage
Epizyme has only been the subject of 3 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Epizyme has received 465 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Epizyme has received 362 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Epizyme has received 56.23% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Epizyme does not currently pay a dividend.
Dividend Growth
Epizyme does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Epizyme insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,518.00 in company stock.
Percentage Held by Insiders
Only 16.30% of the stock of Epizyme is held by insiders.
Percentage Held by Institutions
88.95% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Epizyme are expected to grow in the coming year, from ($2.36) to ($2.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Epizyme is -9.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Epizyme is -9.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Epizyme has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EPZM

Previous Symbol

CUSIPN/A

CIK1571498

Webwww.epizyme.com

Phone617-229-5872

Debt

Debt-to-Equity Ratio0.22

Current Ratio14.81

Quick Ratio14.74

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$23.80 million

Price / Sales78.89

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.01 per share

Price / Book6.17

Profitability

EPS (Most Recent Fiscal Year)($1.93)

Net Income$-170,290,000.00

Net Margins-1,111.58%

Return on Equity-67.19%

Return on Assets-48.52%

Miscellaneous

Employees124

Outstanding Shares101,060,000

Market Cap$1.88 billion

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

How has Epizyme's stock been impacted by COVID-19 (Coronavirus)?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EPZM shares have increased by 0.7% and is now trading at $18.58. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Epizyme?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Epizyme.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Epizyme.

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.74) by $0.23. The biopharmaceutical company had revenue of $1.35 million for the quarter, compared to analysts' expectations of $2.63 million. Epizyme had a negative return on equity of 67.19% and a negative net margin of 1,111.58%. View Epizyme's earnings history.

What price target have analysts set for EPZM?

7 brokerages have issued 12-month price targets for Epizyme's shares. Their forecasts range from $17.00 to $36.00. On average, they expect Epizyme's stock price to reach $30.71 in the next twelve months. This suggests a possible upside of 65.3% from the stock's current price. View analysts' price targets for Epizyme.

Has Epizyme been receiving favorable news coverage?

News articles about EPZM stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Epizyme earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutEpizyme.

Who are some of Epizyme's key competitors?

Some companies that are related to Epizyme include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT) and Nektar Therapeutics (NKTR). View all competitors.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), Clovis Oncology (CLVS), Micron Technology (MU), Sangamo Therapeutics (SGMO), Nektar Therapeutics (NKTR), Novavax (NVAX), Intercept Pharmaceuticals (ICPT) and ImmunoGen (IMGN).

Who are Epizyme's key executives?

Epizyme's management team includes the following people:

Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (13.42%), Redmile Group LLC (8.68%), BlackRock Inc. (6.76%), State Street Corp (2.47%), Victory Capital Management Inc. (2.16%) and Victory Capital Management Inc. (2.16%). Company insiders that own Epizyme stock include David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal. View institutional ownership trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Loomis Sayles & Co. L P, Morgan Stanley, Foresite Capital Management II LLC, JPMorgan Chase & Co., Tekla Capital Management LLC, and BlackRock Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal. View insider buying and selling activity for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Invesco Ltd., Corriente Advisors LLC, Geode Capital Management LLC, AQR Capital Management LLC, Federated Hermes Inc., Two Sigma Investments LP, and AlphaCrest Capital Management LLC. View insider buying and selling activity for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $18.58.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.88 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff